Safety and efficacy of transcatheter arterial micro embolization (TAME) using Imipenem / Cilastatin (IPM/CS) for chronic musculoskeletal pain refractory to non-surgical management.

Safety and efficacy of transcatheter arterial micro embolization (TAME) using Imipenem / Cilastatin (IPM/CS) for chronic musculoskeletal pain refractory to non-surgical management. - Safety and efficacy of TAME for chronic musculoskeletal pain refractory to non-surgical management.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026094

Enrollment

Registered

2017-04-02

Start date

2017-04-02

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Musculoskeletal chronic pain refractory to non-surgical management(Glenohumeral joint, elbow joint, hip joint and knee joint)

Interventions

Transcatheter arterial micro-embolization using IPM/CS

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Previous conservative therapies applied for at least 3 months and persistent moderate-to-severe pain(NRS > 50mm). 2) Elbow, shoulder, hip, knee joint pain. For example, Patients with following diagnosis: adhesive capsulitis, musculoskeletal shoulder pain, tendinopathy and enthesopathy, sinovitis and bursitis, mild osteoarthritis (KL<3), infrapatellar fat pad inflammation, and residual or reccurent pain after knee replacement surgery. 3) Patients who maintain major organ (bone marrow, heart, liver, lung, kidney)function. 4) Below 80 years old in age at the time of the agreement acquisition 20 years old or older. 5) Patients who going to hospital follow-up after this treatment enforcement is possible. 6) Provided written informed consent to undergo the procedure. 7) Patients who abnormal vessels are recognized in an angiography.

Exclusion criteria

Exclusion criteria: 1)Adaptation of treating surgically. 2)Neoplasm 3)Severe arteriosclerosis 4)Pregnant female, female with the possibility of the pregnancy or nursing female 5)6)Iodine Allergy 7)IPM/CS Allergy 8)Using sodium valproate 9)Patients with the past of hypersensitivity for carbapenem system, penicillin system or cephem antibiotics. 10)Severe depression 11)Uncontrollable severe diabetes mellitus 12)Patients who have difficulty in going to hospital follow-up after this treatment enforcement. 13)Patients who abnormal vessels are not recognized in an angiography.

Design outcomes

Primary

Measure	Time frame
Numerical Rating Scale(NRS)of pain.	—

Secondary

Measure	Time frame
Feasibility of TAME. Region of joint. QOL using EQ5D. Imaging of MRI.	—

Countries

Japan

Contacts

Public ContactYasufumi Ohuchi

Tottori university, Faculty of medicine Department of radiology

yasutori0513@yahoo.co.jp0859-38-6637

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026